Correction of Monogenic and Common Retinal Disorders with Gene Therapy
AbstractThe past decade has seen major advances in gene‐based therapies, many of which show promise for translation to human disease. At the forefront of research in this field is ocular disease, as the eye lends itself to gene‐based interventions due to its accessibility, relatively immune‐privileged status, and ability to be non‐invasively monitored. A landmark study in 2001 demonstrating successful gene therapy in a large‐animal model for Leber congenital amaurosis set the stage for translation of these strategies from the bench to the bedside. Multiple clinical trials have since initiated for various retinal diseases, and further improvements in gene therapy techniques have engendered optimism for alleviating inherited blinding disorders. This article provides an overview of gene‐based strategies for retinal disease, current clinical trials that engage these strategies, and the latest techniques in genome engineering, which could serve as the next frontline of therapeutic interventions. View Full-Text
Scifeed alert for new publicationsNever miss any articles matching your research from any publisher
- Get alerts for new papers matching your research
- Find out the new papers from selected authors
- Updated daily for 49'000+ journals and 6000+ publishers
- Define your Scifeed now
Sengillo, J.D.; Justus, S.; Cabral, T.; Tsang, S.H. Correction of Monogenic and Common Retinal Disorders with Gene Therapy. Genes 2017, 8, 53.
Sengillo JD, Justus S, Cabral T, Tsang SH. Correction of Monogenic and Common Retinal Disorders with Gene Therapy. Genes. 2017; 8(2):53.Chicago/Turabian Style
Sengillo, Jesse D.; Justus, Sally; Cabral, Thiago; Tsang, Stephen H. 2017. "Correction of Monogenic and Common Retinal Disorders with Gene Therapy." Genes 8, no. 2: 53.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.